Privium Fund Management B.V. Bei Gene, Ltd. Transaction History

Privium Fund Management B.V.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Jul 28, 2022	SELL	$121.11 - $216.05 $1.82 Million - $3.24 Million	-15,000 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$146.52 - $269.56 $2.2 Million - $4.04 Million	15,000 New	15,000 $2.83 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.4B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

Stay updated on Privium Fund Management B.V. with notifications on news.